cytarabine

P2, N=26, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting

P=N/A, N=22, Not yet recruiting, Henan Provincial People's Hospital; Henan Provincial People's Hospita,medical

P=N/A, N=71, Recruiting, Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College ,Huazhong University o

We predicted potential therapeutic small molecular drugs by targeting subtype-specific oncogenic pathways and validated drug sensitivity (C1-GBM: Methotrexate and Cisplatin; C2-GBM: Cytarabine) by assessing IC50 values against GBM cell lines (divided into C1/C2 subtypes based on the nine hub genes) from the Genomics of Drug Sensitivity in Cancer database. This study introduces a pathway-based prognostic molecular classification of GBM with "hot" (C1-GBM) and "inherent driving" (C2-GBM) tumor subtypes, providing a prediction model based on hub biomarkers and potential therapeutic targets for treatments.

Cases of myelofibrosis transforming into MS are extremely rare. The TP53 mutation is a key molecular marker associated with poor tumor prognosis. Because it can be easily mistaken for other tumors, it is crucial to perform relevant examinations and establish a clear diagnosis as early as possible. This facilitates the timely formulation of an appropriate treatment plan and may help prolong the patient's life.

By targeting nucleic acids, FLT3 or CD33, several FDA-approved NPs and NPDs (i.e., cytarabine, anthracyclines, midostaurin, melphalan and calicheamicin linked to anti-CD33) are the major agents of upfront treatment of AML. This review summarizes the current state of the art, and provides a summary of selected NPs/NPDs which are either entering or have been investigated in preclinical and clinical trials, alone or in combination with current chemotherapy. With multifaceted actions, these biomolecules may target all hallmarks of AML, including multidrug resistance and deregulated metabolism.

P1, N=26, Completed, Baylor College of Medicine | Active, not recruiting --> Completed

P1, N=37, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Feb 2026 --> Sep 2027

P1, N=16, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Mar 2026

P2, N=102, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting

P3, N=167, Terminated, Delta-Fly Pharma, Inc. | N=450 --> 167 | Trial completion date: Jun 2026 --> Jan 2026 | Recruiting --> Terminated; The data met the protocol-specified criteria for futility of the investigational treatment.

P2, N=36, Recruiting, National University Hospital Singapore